
Aitia, a leader in Causal AI and Digital Twins, accelerates drug discovery and R&D in various diseases with global partners.
Aitia, founded with a mission to revolutionize drug discovery, specializes in the application of Causal AI and Digital Twins technology. The company leverages multi-omic patient data, high-performance computing, and causal learning to uncover hidden biological mechanisms of diseases. Aitia's Gemini Digital Twins are instrumental in accelerating research and development in oncology, neurodegenerative disorders, and immunology, aiming to discover novel therapies and expedite the drug development process.
Notable figures associated with Aitia include CEO Colin Hill, who actively promotes the innovative use of AI in drug discovery. The company has formed significant collaborations, such as with Servier to focus on Parkinson’s disease. Aitia's groundbreaking work in Causal AI and Digital Twins has positioned it as a leader in the biotech industry, driving forward the next generation of breakthrough drugs and making a substantial impact on global healthcare research and development.

ConcertAI
concertai.com

Pathos AI
pathos.com

Insitro
insitro.com

BioAI Health
bioaihealth.com

Insilico Medicine
insilico.com

Owkin
owkin.com

Gatc Health
gatchealth.com

Enable Medicine
enablemedicine.com

Cognaisent
cognaisent.com

Ordaos
ordaos.bio

TandemAI
tandemai.com

Biotia
biotia.io

Triomics
triomics.com

Noetik
noetik.ai

Ambit.AI
ambit.ai
Companies similar to Aitia include ConcertAI, Pathos AI, Insitro and BioAI Health.
Aitia was founded in 2000.
Aitia's headquarters is located in Somerville, MA, US.
Aitia's most recent funding round was for $23M (USD) in July 2019.
As of Jul 9, 2019, Aitia has raised a total of $77.3M (USD).
Aitia has 88 employees as of Feb 5, 2024.